The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver

被引:66
作者
Girard, Hugo
Villeneuve, Lyne
Court, Michael H.
Fortier, Louis-Charles
Caron, Patrick
Hao, Qin
von Moltke, Lisa L.
Greenblatt, David J.
Guillemette, Chantal
机构
[1] CHU Laval, Oncol & Mol Endocrinol Res Ctr, Canada Res Chair Pharmacogen, Lab Pharmacogen, Quebec City, PQ G1V 4G2, Canada
[2] Univ Laval, Fac Pharm, Quebec City, PQ G1K 7P4, Canada
[3] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
关键词
METASTATIC COLORECTAL-CANCER; PROMOTER REGION; GENE PROMOTER; IRINOTECAN; 1A1; METABOLISM; TOXICITY; IMPACT; SN-38; IDENTIFICATION;
D O I
10.1124/dmd.106.009787
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Polymorphisms in UGT1A9 were associated with reduced toxicity and increased response to irinotecan in cancer patients. UDP-glucuronosyltransferase (UGT) protein expression, glucuronidation activities for 7-ethyl-10-hydroxycamptothecin (SN-38), and probe substrates of the UGT1A9 and UGT1A1 were measured in 48 human livers to clarify the role of UGT1A9 variants on the in vitro glucuronidation of SN-38. Genotypes were assessed for UGT1A9 (-2152C > T, -275T > A, and -118T(9 > 10)), three novel UGT1A9 variants (-5366G > T, -4549T > C, and I399C > T), and UGT1A1 (-53TA(6 > 7), -3156G > A, and -3279T > G). Of all the variants, the UGT1A9 I399C > T was associated with the most dramatic change in SN-38-glucuronide (SN-38G) (2.64-fold; p = 0.0007). Compared with UGT1A9 I399C/C, homozygous I399T/T presented elevated UGT1A1 and UGT1A9 proteins and higher glucuronidation of UGT1A9 and UGT1A1 substrates (p < 0.05). The very low linkage disequilibrium (r(2) < 0.19) between UGT1A9 I399 and all the other UGT1A1 and UGT1A9 variants suggests a direct effect or linkage to unknown functional variant(s) relevant to SN-38 glucuronidation. The UGT1A9 -118T9/10 was also linked to alteration of SN-38 glucuronidation profiles in the liver (p < 0.05) and was associated with higher UGT1A1 protein (p = 0.03). However, UGT1A9 -118T10 appears to have low functional impact as a result of the lack of correlation with UGT1A9 protein levels and a modest 1.4-fold higher reporter gene expression associated with the -118T10 allele in HepG2 cells (p = 0.004). In contrast, the UGT1A9 -5366T, -4549C, -2152T, and -275A, associated with higher UGT1A9 protein (2-fold; p < 0.05), have no influence on SN-38G. Despite limitations resulting from sample size, results indicate that UGT1A9 I399 and -118T(9/10) may represent additional candidates in combination with UGT1A1 promoter haplotypes for the prediction of SN-38 glucuronidation profile in vivo.
引用
收藏
页码:1220 / 1228
页数:9
相关论文
共 32 条
[1]  
Ando Y, 2000, CANCER RES, V60, P6921
[2]   THE GENETIC-BASIS OF THE REDUCED EXPRESSION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IN GILBERTS-SYNDROME [J].
BOSMA, PJ ;
CHOWDHURY, JR ;
BAKKER, C ;
GANTLA, S ;
DEBOER, A ;
OOSTRA, BA ;
LINDHOUT, D ;
TYTGAT, GNJ ;
JANSEN, PLM ;
ELFERINK, RPJO ;
CHOWDHURY, NR .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (18) :1171-1175
[3]  
Carlini LE, 2005, CLIN CANCER RES, V11, P1226
[4]   Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTS):: S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9 [J].
Court, MH ;
Duan, SX ;
Guillemette, C ;
Journault, K ;
Krishnaswamy, S ;
Von Moltke, LL ;
Greenblatt, DJ .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (11) :1257-1265
[5]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[6]   A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity [J].
Duguay, Y ;
Báár, C ;
Skorpen, F ;
Guillemette, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (03) :223-233
[7]   The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk [J].
Duguay, Y ;
McGrath, M ;
Lépine, J ;
Gagné, JF ;
Hankinson, SE ;
Colditz, GA ;
Hunter, DJ ;
Plante, M ;
Têtu, B ;
Bélanger, A ;
Guillemette, C ;
De Vivo, I .
CANCER RESEARCH, 2004, 64 (03) :1202-1207
[8]   Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) [J].
Gagné, JF ;
Montminy, V ;
Belanger, P ;
Journault, K ;
Gaucher, G ;
Guillemette, C .
MOLECULAR PHARMACOLOGY, 2002, 62 (03) :608-617
[9]   UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver [J].
Girard, H ;
Thibaudeau, J ;
Court, MH ;
Fortier, LC ;
Villeneuve, L ;
Carom, P ;
Hao, Q ;
von Moltke, LL ;
Greenblatt, DJ ;
Guillemette, C .
HEPATOLOGY, 2005, 42 (02) :448-457
[10]   Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver [J].
Girard, H ;
Court, MH ;
Bernard, O ;
Fortier, LC ;
Villeneuve, L ;
Hao, Q ;
Greenblatt, DJ ;
von Moltke, LL ;
Perussed, L ;
Guillemette, C .
PHARMACOGENETICS, 2004, 14 (08) :501-515